Petros Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Fady Boctor

İcra Kurulu Başkanı

US$875.1k

Toplam tazminat

CEO maaş yüzdesi	40.0%
CEO görev süresi	4.8yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	3.9yrs

Son yönetim güncellemeleri

Recent updates

Petros Pharmaceuticals GAAP EPS of -$0.10, revenue of $6.6M

Aug 15

Petros Pharma shares more than triple in value after co to be taken private in $67.2M deal

Jul 28

Petros Pharmaceuticals: Advancing Complementary Men's Health Therapeutics

Dec 07

CEO Tazminat Analizi

Fady Boctor'un ücretlendirmesi Petros Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$21m
Mar 31 2024	n/a	n/a	-US$20m
Dec 31 2023	US$875k	US$350k	-US$14m
Sep 30 2023	n/a	n/a	-US$13m
Jun 30 2023	n/a	n/a	-US$22m
Mar 31 2023	n/a	n/a	-US$21m
Dec 31 2022	US$682k	US$350k	-US$20m
Sep 30 2022	n/a	n/a	-US$24m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$12m
Dec 31 2021	US$1m	US$350k	-US$9m
Sep 30 2021	n/a	n/a	-US$6m
Jun 30 2021	n/a	n/a	-US$8m
Mar 31 2021	n/a	n/a	-US$11m
Dec 31 2020	US$468k	US$276k	-US$21m
Sep 30 2020	n/a	n/a	-US$24m
Jun 30 2020	n/a	n/a	-US$29m
Mar 31 2020	n/a	n/a	-US$32m
Dec 31 2019	US$340k	US$208k	-US$33m

Tazminat ve Piyasa: Fady 'nin toplam tazminatı ($USD 875.10K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 653.78K ).

Tazminat ve Kazançlar: Fady şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Fady Boctor (46 yo)

4.8yrs

Görev süresi

US$875,096

Tazminat

Mr. Fady Boctor, MBA, has been the President and Chief Commercial Officer of Petros Pharmaceuticals, Inc. since 2020. Mr. Boctor has experience in the pharmaceutical industry, across a wide array of functi...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joshua Silverman	Independent Chairman of the Board	3.9yrs	US$309.30k	0.11% $ 3.8k
Wayne Walker	Independent Director	3.9yrs	US$147.97k	0.083% $ 2.8k
Bruce Bernstein	Independent Director	3.9yrs	US$147.97k	0.083% $ 2.8k

3.9yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PTPI 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.9 yıldır).

Petros Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Petros Pharmaceuticals, Inc. Announces Board Resignations

Petros Pharmaceuticals, Inc., Annual General Meeting, Nov 20, 2024

Insufficient new directors

Petros Pharmaceuticals, Inc., Annual General Meeting, Dec 29, 2023

High number of new and inexperienced directors

Petros Pharmaceuticals, Inc., Annual General Meeting, Nov 29, 2022

Recent updates

Petros Pharmaceuticals, Inc. Announces Board Resignations

Petros Pharmaceuticals, Inc., Annual General Meeting, Nov 20, 2024

Petros Pharmaceuticals, Inc. Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Petros Pharmaceuticals, Inc. Announces Results of First of Series of Pivotal Studies Aimed at Facilitating FDA-Approved OTC Access of STENDRA (Avanafil) for Consumers

Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Petros Pharmaceuticals Receives Positive Response from Fda Following Recent Demonstration of Technology Component in Pursuit of Otc Status for Stendra(R) (Avanafil)

New major risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

Petros Pharmaceuticals, Inc. Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA (avanafil) as it Pursues OTC Status

Insufficient new directors

Petros Pharmaceuticals, Inc. Announces Successful Completion of the Initial Cohort of A Phase 2 Equivalent Self-Selection Study

Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status

Petros Pharmaceuticals, Inc., Annual General Meeting, Dec 29, 2023

Petros Pharmaceuticals, Inc. announced delayed 10-Q filing

Petros Pharmaceuticals Announces to Develop Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)

Petros Pharmaceuticals, Inc. Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA

Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential Otc Stendra Label

Second quarter 2023 earnings released: US$1.20 loss per share (vs US$0.88 loss in 2Q 2022)

Petros Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding

First quarter 2023 earnings released: US$0.66 loss per share (vs US$0.084 loss in 1Q 2022)

Third quarter 2022 earnings released: US$0.67 loss per share (vs US$0.17 loss in 3Q 2021)

High number of new and inexperienced directors

Petros Pharmaceuticals, Inc. Announces Expansion of FDA Labeling for Its Oral Erectile Dysfunction Drug, STENDRA

Petros Pharmaceuticals, Inc., Annual General Meeting, Nov 29, 2022

Petros Pharmaceuticals GAAP EPS of -$0.10, revenue of $6.6M

Second quarter 2022 earnings released: US$0.088 loss per share (vs US$0.22 loss in 2Q 2021)

Petros Pharma shares more than triple in value after co to be taken private in $67.2M deal

Petros Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

First quarter 2022 earnings released: US$0.008 loss per share (vs US$0.31 profit in 1Q 2021)

Petros Pharmaceuticals, Inc. Announces They Will Be Pursuing the 505(B)(2) Pathway for Its Investigational Agent

High number of new and inexperienced directors

Petros Pharmaceuticals, Inc. Announces Positive Results of Over-The-Counter (Otc) Label Comprehension Study for Erectile Dysfunction Drug STENDRA

Full year 2021 earnings released: US$0.82 loss per share (vs US$3.86 loss in FY 2020)

Petros Pharmaceuticals Launches Two Self-Selection Studies for Erectile Dysfunction Drug Stendra (Avanafil)

Petros Pharmaceuticals, Inc. announced that it has received $2.200023 million in funding

Petros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5.299978 million.

Petros Pharmaceuticals, Inc. announced that it expects to receive $2.200023 million in funding

Petros Pharmaceuticals Announces Positive Over-the-Counter Label Comprehension Study Results for Erectile Dysfunction Drug STENDRA

Petros Pharmaceuticals: Advancing Complementary Men's Health Therapeutics

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.96 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.22 loss per share (vs US$1.68 loss in 2Q 2020)

Petros Pharmaceuticals, Inc. Completes Pilot Label Comprehension Study to Initiate Process for Stendra® Prescription Erectile Dysfunction Medication to Achieve Designation as an Over-the-Counter Treatment

Petros Pharmaceuticals, Inc.(NasdaqCM:PTPI) dropped from Russell Microcap Growth Index

First quarter 2021 earnings released: EPS US$0.31 (vs US$1.77 loss in 1Q 2020)

New 90-day low: US$3.22

Petros Pharmaceuticals Appoints Dr. Mohit Khera to Steering Committee

Petros Pharmaceuticals, Inc. Appoints Mitchell Arnold to Serve as the Principal Financial Officer and Principal Accounting Officer

Petros Pharmaceuticals, Inc. Announces Executive Changes

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş